$AZN AstraZeneca Tape Reports
Per Ticker.id: $AZN AstraZeneca Tape Reports — 77 podcast mentions across 8 podcasts (30 days), latest 2026-08-17 16:45 UTC.
Unbelievable. So here's one where, uh, not working out so well. AstraZeneca is stopping a clinical trial of the experimental drug— I'm not going to pronounce it— after it didn't look set to help fight lung cancer better than existing therapy. So I'm going to go to Sam Fazzelli. He does all this healthcare stuff for Bloomberg Intelligence. He's based in London. I have no idea where he is right now. But Sam, talk to us about AstraZeneca and just about this drug in particular, but just how these big pharma companies kind of try to pursue a portfolio approach of drug development. Yeah.
Paul Sweeney — Bloomberg Intelligence · Family Offices Amass $3.8 Billion SpaceX Bet in Boost for Musk · 2026-08-17Hello, good day, Luke and Justin. Longtime listener here from the Midwest. Love the show. Thank you guys for everything you do. I have a question here I'd like your advice on, please. Trying to complete out, uh, another holding for my, uh, healthcare side of my portfolio. And I'm looking at, um, JNJ, Johnson Johnson. Then I also was looking at AZN, AstraZeneca, which I know you guys speak highly of. And I wasn't sure which of those, I guess, to make up my mind about, or which one you thought might be better. But then I came across VHL, HEALTHTECH ETF fund that holds all healthcare stocks, different companies. I was wondering your advice on this. Would that be maybe my best choice to select? That ETF has been going up very nicely, pays a little dividend, but it has all the stocks I mentioned in its holdings. I was wondering if that might be the best choice for me to make, and I wouldn't have to worry about it. Hold a lot of the medical sector and be good to go. I'll be listening on the show for your advice. Thank you very much. Have a good day.
Speaker D — InvestTalk · Soft Jobs Report and the Dollar's New Direction: What It Means for Investors · 2026-08-15All right, looking at VHT, and this is the Vanguard Healthcare ETF. And if you want broad-based exposure, this is fine. You're gonna pay only, let's see, 9 basis points, so pretty low expense ratio. 423 different names in here, but you're heavily weighted towards Eli Lilly. That's 14% of the portfolio. But then Johnson Johnson is right around 9%, AbbVie around 6.5%, UnitedHealth around 5.5%. Let's see, when do we get to AstraZeneca? It kind of depends on what you, what you want. Do you want just simple exposure? This is a good Way to get it. If you really like a particular name, like we really like AstraZeneca and its business and its growth and its valuation, its profitability, et cetera. That's why we own it. We also like a bit of foreign exposure, but that brings more individual risk. So I think it also depends on what percentage of your portfolio you're trying to get in healthcare. If it's 8, 10%, something like that, That's when you probably want something that's broad-based exposure as opposed to one name like an AstraZeneca or even a Johnson Johnson. So I think for you, probably the simple answer is just buy VHT. That was Invest Talk. I'm Justin Klein. We have one goal here each and every weekday is help you achieve your own version of financial freedom. And our work continues after this final break. So get your questions in right now at 888-99-Sharp.
Justin Klein — InvestTalk · Soft Jobs Report and the Dollar's New Direction: What It Means for Investors · 2026-08-15